NCT06572384招募中3 期
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belimumab Administered Subcutaneously in Adults With Interstitial Lung Disease (ILD) Associated With Connective Tissue Disease (CTD)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 440
- 试验地点
- 146
- 主要终点
- Absolute Change from Baseline in Forced Vital Capacity (FVC) milliliter (mL) at Week 52
研究概览
简要总结
Interstitial lung disease (ILD) is a lung condition resulting in inflammation and stiffening of the lung, often associated with connective tissue diseases (CTDs). ILD causes reduction in lung volume, shortness of breath, cough and fatigue therefore has high impact on quality of life and is also the leading cause of death in participants with these conditions. The study will assess whether treatment of CTD-ILD participants with belimumab in addition to standard therapy will result in the stabilization and/or improvement of lung function and improve symptoms associated with ILD with an acceptable safety profile.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
This is a double-blind study.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants with persistent/worsening active inflammatory disease who have failed to achieve their treatment goal, i. e., those who have experience lack of expected treatment benefit (clinically meaningful improvement in FVC), fail to demonstrate sustained lung function stability or continue to experience worsening of ILD despite initiation of standard therapy or failed to tolerate standard therapy.
- •Documented diagnosis of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM; including polymyositis, dermatomyositis, anti-synthetase syndrome), Sjogren's syndrome (pSS), or mixed connective tissue disease (MCTD) in accordance with internationally recognized classification criteria
- •Diagnosis of inflammatory and/or fibrotic ILD on High Resolution Computed Tomography (HRCT) with a total disease extent of greater than or equal to (≥) 10% of the whole lung
- •Evidence of persistent active/worsening ILD
- •Must be currently receiving stable standard therapy to manage ILD and/or underlying CTD, or to have failed or failed to tolerate standard therapy.
- •Participant is capable and willing to self-administer the study medication or has a caregiver who is capable and willing to administer the study medication throughout the study
- •A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:
- •Is a woman of nonchildbearing potential (WONCBP) OR
- •Is a Woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective, with a failure rate of less than (<)1%
- •Capable of giving signed informed consent
排除标准
- •Diagnosis of ILD other than CTD-ILD.
- •Primary diagnosis of Systemic Sclerosis (SSc).
- •Participants with rapidly progressive disease (absolute drop of 10% or more of FVC between screening and baseline visit and/or recent pulmonary hospitalization).
- •FVC ≤ 45% of predicted, or a Diffusing Capacity of the lung for Carbon Monoxide (DLco) (corrected for hemoglobin) ≤ 40% of predicted at screening as confirmed by central reader
- •History or presence of diffuse alveolar hemorrhage (DAH) or other confounding pulmonary disease, signs, or symptoms
- •Pulmonary arterial hypertension requiring therapy, as determined by the investigator at, or prior to first day of dosing (Day 1)
- •Dependence on continuous oxygen supplementation
- •History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data
- •Obstructive pulmonary disease (pre-bronchodilator Forced Expiratory Volume (FEV1) /FVC <0.7) as confirmed by central reader
- •Significant emphysema on screening or historical HRCT (extent of emphysema exceeds extent of ILD) as confirmed by central reader
- •Confirmed Progressive multifocal leukoencephalopathy (PML) or unexplained new-onset or deteriorating neurologic signs and symptoms
- •Participants with patient health questionnaire (PHQ-9) score ≥10, that in the opinion of a mental healthcare professional pose a serious suicide risk, have or any history of suicidal behavior in the last 6 months and/or any suicidal ideation in the last 2 months, or who in the investigator's judgment, poses a significant suicide risk.
- •Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years
- •Breast cancer within the past 10 years
- •Major surgery (including joint surgery) within 3 months prior to screening or planned during the duration of the study
- •An active infection, or a history of infections
研究组 & 干预措施
Placebo
Placebo Comparator
Participants will receive placebo in addition to standard therapy.
干预措施: Placebo (Other)
Belimumab
Experimental
Participants will receive belimumab in addition to standard therapy.
干预措施: Belimumab (Biological)
结局指标
主要结局
Absolute Change from Baseline in Forced Vital Capacity (FVC) milliliter (mL) at Week 52
时间窗: Baseline and Week 52
Forced vital capacity is the total amount of air exhaled during the lung function test. Low FVC (mL) reflects more impaired lung function. Absolute Change from Baseline in FVC will be reported.
次要结局
- Absolute Change from Baseline in FVC Percentage (%) Predicted at Week 52(Baseline and Week 52)
- Time to ILD Progression or Death(From the date of assignment (Day 1) until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 52 Weeks)
- Number of Participants with Respiratory Related Hospitalizations up to Week 52(Up to Week 52)
- Absolute Change from Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Score at Week 52(Baseline and Week 52)
- Absolute Change from Baseline in Living with Pulmonary Fibrosis (L-PF) Total Symptom Score at Week 52(Baseline and Week 52)
- Absolute Change from Baseline in Quantitative Interstitial Lung Disease in the Whole Lung (QILD-WL) At Week 52(Baseline and Week 52)
- Absolute Change from Baseline in Quantitative Measures of Lung Fibrosis (QLF) in the Whole Lung At Week 52(Baseline and Week 52)
- Achieving Relative Decline from Baseline in FVC (mL) ≥ 5% at Week 52(Baseline and Week 52)
- Achieving Relative Decline from Baseline in FVC (mL) ≥ 10% at Week 52(Baseline and Week 52)
- Absolute Change from Baseline in Steroid Dose (Prednisone Equivalent Dose) at Week 52(Baseline and Week 52)
- Time to Connective Tissue Disease Progression(Up to 52 Weeks)
- Absolute Change from Baseline in Transition Dyspnea Index (TDI) at Week 52(Baseline and Week 52)
- Absolute Change from Baseline in Short Form Health Survey 36-Item Version 2 (SF36-v2) at Week 52(Baseline and Week 52)
- Absolute Change from Baseline in Living with Pulmonary Fibrosis (L-PF) Impacts Total Score at Week 52(Baseline and Week 52)
- Absolute Change from Baseline in Physician Global Assessment (PhGA) at Week 52(Baseline and Week 52)
- Absolute Change in Patient Global Impression of Change (PGIC)-ILD at Week 52(Baseline and Week 52)
- Absolute Change from Baseline in Diffusing Capacity of the Lung for Carbon Monoxide (DLco) % Predicted at Week 52(Baseline and Week 52)
- Number of Participants with Adverse Events (AEs), Adverse Events of Special Interest (AESIs) Serious Adverse Events (SAEs)(Up to Week 60)
- Absolute Change from Baseline in Quantitative Ground Glass Opacity in the Whole Lung (QGGO-WL) at Week 52(Baseline and Week 52)
- Absolute Change from Baseline in King's Brief Interstitial Lung Disease Questionnaire (K-BILD) at Week 52(Baseline and Week 52)
研究者
研究点 (146)
Loading locations...
相似试验
已完成
2 期
Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILDSclerodermaIdiopathic Inflammatory MyositisMixed Connective Tissue DiseaseInterstitial Lung DiseaseNCT01862926Royal Brompton & Harefield NHS Foundation Trust104
招募中
2 期
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Qifangfeixian Granules in the Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD)Qifangfeixian GranulesInterstitial Lung DiseaseNCT06674148Huilan Zhang124
已完成
3 期
A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)Lung Diseases, InterstitialNCT05321082Boehringer Ingelheim1,178
进行中（未招募）
不适用
Interstitial Lung Disease Exacerbations StudyInterstitial Lung Disease (ILD)Pulmonary FibrosisNCT06685874Royal Devon and Exeter NHS Foundation Trust1,500
已完成
3 期
A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung FibrosisLung Diseases, InterstitialNCT05065190Boehringer Ingelheim81